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OBJECTIVES The purpose of the study was to determine whether the well tolerated serotonin reuptake
inhibitor paroxetine hydrochloride could prevent vasovagal syncope in patients resistant to or
intolerant of previous traditional therapies.
BACKGROUND Serotonergic mechanisms play a major role in the processes leading to neurocardiogenic
vasovagal syncope, and serotonin reuptake inhibitors have been reported to be effective in
preventing refractory syncope.
METHODS Sixty-eight consecutive patients (26 men and 42 women, mean age 44.7 6 16.5 years) with
recurrent syncope and positive head-up tilt test and in whom standard therapies with
beta-adrenergic blocking agents, vagolytic, negative inotropic or mineral corticoid agents were
ineffectual or poorly tolerated were referred for study. Patients randomly received either
paroxetine at 20 mg once a day or a placebo. A head-up tilt test was then reperformed after
one month of treatment, and the clinical effect was noted over a mean follow-up of 25.4 6
7.9 months.
RESULTS The response rates (negative tilt test) after one month of treatment were 61.8% versus 38.2%
(p , 0.001) in the paroxetine and placebo groups, respectively. During follow-up spontaneous
syncope was reported in six patients (17.6%) in the paroxetine group as compared to 18
patients (52.9%) in the placebo group (p , 0.0001). Only one patient (2.9%) asked to be
discontinued from the drug for severe side effects.
CONCLUSIONS Paroxetine was found to significantly improve the symptoms of patients with vasovagal
syncope unresponsive to or intolerant of traditional medications and was well tolerated by
patients. (J Am Coll Cardiol 1999;33:1227–30) © 1999 by the American College of
Cardiology
Recurrent syncope is a common clinical problem that lacks
adequate treatment. The exact pathophysiologic mechanism
of vasovagal syncope remains unclear and represents a
fascinating challenge to the clinicians who try to explain
why this phenomenon occurs. The introduction of head-up
tilt testing almost ten years ago (1) provided a simple
laboratory test to evaluate for neurally mediated syncope.
In individuals predisposed to neurocardiogenic syncope,
the assumption of a passive upright posture leads to gravi-
tationally mediated venous pooling of blood in the lower
extremities. This downward displacement of intravascular
volume results in a significant decrease of cardiac output,
and arterial baroreceptor reflexes are activated, resulting in a
reflex increase in sympathetic stimulation (2–4). The sym-
pathetically mediated increase in contractility in a preload
reduced left ventricular cavity (5) is believed to activate
unmyelinated vagal C-fibers (ventricular mechanorecep-
tors). Stimulation of these receptors produces a large affer-
ent signal to the brain stem and inhibition of sympathetic
outflow occurs (4–7).
Several neurotransmitters are believed to facilitate vaso-
vagal reactions by inhibiting the neuroadrenergic system. In
addition to catecholamines (8,9), opioid peptides (9,10),
arginin-vasopressin (11), nitric oxide (11) and adenosine
(12), it has been reported that 5-hydroxy-triptamine (sero-
tonin) may play an important role in the modulation of
central nervous blood pressure and heart rate regulation
thus, fluctuations in central serotonin levels being supposed
to facilitate the pathogenesis of neurocardiogenic vasovagal
syncope. As reported in experimental models, the sudden
sympathetic withdrawal responsible for vasovagal syncope
appears quite similar to that produced by the injection of
serotonin into the intercerebral ventricular areas (13,14).
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Several studies have been undertaken to evaluate the
efficacy of pharmacotherapy on vasovagal syncope, but a real
gold standard of tilt-guided therapy has not been estab-
lished yet.
Selective serotonin reuptake inhibition by fluoxetine or
sertraline has been reported to be effective in patients with
refractory vasovagal syncope, but these trials have not been
placebo-controlled (15–17). Thus, to determine whether
the new, well-tolerated, serotonin reuptake inhibitor parox-
etine would have similar effects in patients with refractory
vasovagal syncope and positive head-up tilt table test, the
following randomized, double-blind, placebo-controlled
study was undertaken.
METHODS
Study population. Sixty-eight consecutive patients (26
men and 42 women, mean age 44.7 6 16.5 years) with
refractory syncope and nitrate-potentiated tilt test were
referred for study. Etiology of syncope remained unex-
plained despite a complete history and physical examination
which included: cardiologic and neurologic assessment,
computed axial tomography or magnetic resonance of the
brain, neck vessel Doppler flowmeter, carotid sinus massage
and blood pressure determination (both supine and ortho-
static), 12-lead electrocardiogram, chest X-ray, routine lab-
oratory tests, two dimensional echocardiography and 24-h
Holter monitoring and exercise stress test. Electrophysiol-
ogy was performed when brady- or tachyarrhythmias were
suspected of being responsible for the incidence of faintings.
Patients had no clinical major endogenous depression or
panic disorder and were all unresponsive to or intolerant of
previous therapies. The study was performed according to
the guidelines of the institutional committee on human
research. All patients gave written informed consent.
Tilt test protocol. Patients underwent head-up tilt test
between 10 a.m. and 12 a.m. after a 12 h fasting period.
After baseline blood pressure and heart rate value measure-
ments, each patient was tilted to 60° for up to 45 min (18).
If syncope developed during the tilt, the patient was
immediately lowered to the supine position, and the study
ended. If no symptoms developed, the test was prolonged
for up to 20 min after 5 mg sublingual isosorbide dinitrate
(Carvasin, Wyeth, Havant, United Kingdom) administra-
tion (19). Blood pressure was recorded by an automatic
sphygmomanometer (Criticon Dinamapp) on the right arm
while heart rate was monitored by a 12-channel electro-
cardiogram (Hewlett-Packard Pagewriter XLi, Cupertino,
California). A positive head-up tilt test was defined as the
provocation of hypotension, bradycardia or both associated
with a loss of consciousness that reproduced the patients’
clinical episodes (20).
Previous therapies. In each case, the patients’ traditional
therapies were either ineffectual or poorly tolerated. Failure
was defined as the clinical recurrence of syncope. Patients
had been unresponsive to or intolerant of 75 mg daily of
ethylephrine (17 patients), 80 mg daily of propranolol (20
patients), either ethylephrine or propranolol (23 patients),
600 mg daily of aminophylline (4 patients), 0.2 mg daily of
fludrocortisone (2 patients), 200 mg daily of dysopiramide
(1 patient) and transdermal scopolamine (1 patient). Previ-
ous medications were all discontinued before paroxetine or
placebo treatment.
Study protocol. Each of the sixty-eight patients exhibited
a positive response during tilt testing, were given pharma-
cotherapy and underwent repeat tilt tests. Patients were
computer randomized into two follow-up groups and were
given either oral paroxetine at 20 mg daily (34 patients) or
a placebo tablet (34 patients). Patients, cardiologists and
nurses were all blinded to treatment assigned. Paroxetine
and placebo tablets were quite similar in appearance and
taste, and patients were not able to determine whether they
were on paroxetine or placebo. One month after the
initiation of therapy, the response to the tilt test was
reevaluated in the same laboratory at approximately the
same time of day using the same protocol. Recurrence of
spontaneous syncope was evaluated by a separate cardiolo-
gist over a mean period of 25.4 6 7.9 months. Each of the
sixty-eight patients had a follow-up of at least 24 months
(range 24–33).
Statistical analysis. The response rate of paroxetine and a
placebo was compared by chi square test while other
Table 1. Clinical Characteristics
Characteristics Paroxetine Placebo
p
Value
No. of patients 34 34
Age (yr) 43.2 6 16.4 46.1 6 13.5 0.429
Gender (M/F) 12/22 14/20 0.071
Syncopes/yr 7.2 6 2.1 8.1 6 3.4 0.194
Duration of history (years) 3.8 6 0.9 4.2 6 1.3 0.145
Systolic blood pressure (mm Hg) 119.7 6 17.2 121.4 6 16.8 0.681
Diastolic blood pressure (mm Hg) 72.4 6 11.5 75.1 6 12.1 0.349
Heart rate (beats/min) 76.2 6 14.3 79.2 6 11.7 0.347
Mean positive time (min) 31.4 6 11.2 29.2 6 9.7 0.390
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continuous data were expressed as mean 6 SD and com-
pared by Student t test. A p value less than 0.05 was
considered significant. For multiple statistical comparisons
to baseline, a p value less than 0.025 was considered
significant.
RESULTS
Clinical characteristics (Table 1). Both groups were com-
parable in age and ratio of men to women. Duration of
syncopal histories, severity (yearly recurrence) of attacks,
baseline blood pressure and heart rate values were similar in
both groups. During the first tilt test, the placebo group had
a mean positive time (to syncope onset) at 29.2 6 9.7 min,
and the paroxetine group, 31.4 6 11.2 (p 5 0.390).
Tilt test repetition. Acute tilt-induced syncope was ob-
served in 38.2% (13 patients) versus 61.8% (21 patients) in
the paroxetine and placebo groups, respectively (p 5 0.001).
A significant increase of mean test duration was observed in
the paroxetine group with a mean delay of positive time
from 31.4 6 11.2 min up to 47.8 6 12.4 min (p , 0.001).
Spontaneous syncope and follow-up. Before treatments
were administered, the placebo group had 7.2 6 2.1 yearly
syncopal episodes, and the paroxetine group had 8.1 6 3.4
(p 5 0.194). Spontaneous syncope recurrence during the
two year follow-up was 52.9% (18 patients) versus 17.6% (6
patients) in the placebo and paroxetine groups, respectively
(p , 0.0001). The symptomatic patients in the paroxetine
group also reported that their attacks were reduced from
8.1 6 3.4/year to 5.9 6 1.7/year (p 5 0.001), while no
significant differences were obtained in the placebo group.
No difference in time for recurrence of syncope was ob-
served among the groups. No patients reported feeling
worse during follow-up. Only one patient (2.9%) in the
paroxetine group asked to be discontinued from the drug for
severe recurrent headaches. Two patients in the paroxetine
group (transient sexual dysfunction, nausea and diarrhea)
and one patient in the placebo group (headache) reported
some side effects, but medication was not discontinued.
Once a day drug administration was well-accepted in both
groups.
DISCUSSION
Recurrent syncope can be a severely disabling disorder and
quality of life deteriorates as a function of the recurrence of
episodes.
Not only can these episodes produce physical trauma, but
they create a serious psychological discomfort and employ-
ment, education and social interactions may be severely
restricted.
Therapy. Therapy of vasovagal syncope has largely been
empiric, based on the mechanism that is currently believed
to be the cause of vasovagal faintings. Nevertheless—
irrespective of beta-blocking, vagolytic, negative inotropic,
mineral corticoid therapy—several patients continue to
experience episodes of syncope (refractory syncope). In our
series we studied sixty-eight patients with recurrent syncope
subjected to previous ineffectual or poorly tolerated 75 mg
daily ethylephrine, 80 mg daily propranolol, either ethyl-
ephrine or propranolol, 600 mg daily aminophylline, 0.2 mg
daily fludrocortisone, 200 mg daily dysopiramide or trans-
dermal scopolamine.
Serotonin and vasovagal syncope. The role of central
serotonin metabolism in the pathophysiology of vasovagal
syncope remains controversial. Several pathophysiologic re-
actions similar to vasovagal reflex are believed to be medi-
ated by central serotonin level fluctuations (13,14,21,22).
The first trials with regard to selective serotonin reuptake
inhibition and vasovagal syncope were published by Grubbs
et al. (15–17), but these trials were not placebo-controlled.
The authors reported clinical success (no syncope) in 68.7%
of patients subjected to fluoxetine at 20 mg daily (15) and in
70.6% of those subjected to sertraline at 50 mg daily (16).
Nevertheless, severe side effects were reported in 19% and
17.6% in the fluoxetine and sertraline groups, respectively,
and patients asked to be discontinued from the drug.
Paroxetine therapy. Paroxetine hydrochloride (Seroxat,
Smith Kline Beecham Pharmaceuticals, Mayenne, France)
is a highly selective serotonin reuptake inhibitor, unlike
tricyclic antidepressant agents having poor or no affinity for
adrenergic, cholinergic and hystamine receptors. Protein
binding is about ninety-five percent. Major metabolites of
paroxetine are less powerful serotonin reuptake inhibitors
than the parent compound and are not believed to contrib-
ute to paroxetine’s therapeutic effects. Once a day oral
administration allowed steady state plasma levels within 14
days of treatment and was well accepted by patients. In the
study paroxetine was found to be an effective therapy for
preventing acute tilt-induced (61.8% negative tilt test rep-
etition) and spontaneous syncope (82.4% symptom free) in
patients unresponsive to or intolerant of other forms of
therapy (refractory syncope). The effects of paroxetine on
acute tilt-induced syncope conform to recent reports by
Grubb et al. who tested serotonin reuptake inhibition by
oral fluoxetine (15) and sertraline (16), but data should be
treated with considerable caution given the well-established
lack of reproducibility of tilt tests (70% at best) (23–25) and
the relatively small number of patients. Paroxetine seems to
have major effectiveness in preventing spontaneous syncope
as compared with the other serotonin reuptake inhibitors
investigated (15–17). Moreover, it was well tolerated, side
effects were negligible and only one patient (2.9%) asked to
be discontinued from the drug for severe side effects.
The possible mechanism by which serotonin reuptake
inhibition improves clinical outcome of patients with refrac-
tory neurocardiogenic syncope has been proposed by
Grubb et al. since they postulated that, because of their
facilitation of nerve transmission, serotonin reuptake inhib-
itors cause postsynaptic serotonin receptors down regulation
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in the brain stem. This down regulation in receptor density
is believed to result in a blunted response to rapid shifts in
central serotonin levels (15–17).
Conclusions. We conclude that paroxetine may represent
an effective and well tolerated therapy in patients with
recurrent vasovagal syncope who are unresponsive to or
intolerant of traditional tilt-guided medication. Major series
and longer follow-up periods are needed to resolve the
question of the role of selective serotonin reuptake inhibi-
tors in the prophylaxis of refractory neurocardiogenic syn-
cope.
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